Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
P/E ratio for Arvinas, Inc. (ARVN)
P/E ratio as of 2023: -6.22
According to Arvinas, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.22. At the end of 2022 the company had a P/E ratio of -6.69.
P/E ratio history for Arvinas, Inc. from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -6.22 |
| 2022 | -6.69 |
| 2021 | -22.42 |
| 2020 | -30.04 |
| 2019 | -21.78 |
| 2018 | -2.92 |
| 2017 | -13.84 |
| 2016 | -20.00 |